

## **CALDON BIOTECH INC.**

### **VZV IgG ELISA**

Catalog No. VZ081G  
(96 tests)

#### **NAME AND INTENDED USE**

The CALDON BIOTECH INC. (CBI), Varicella-Zoster Virus IgG ELISA is intended for use in the evaluation of patients with suspected VZV infection.

#### **SUMMARY AND EXPLANATION OF THE TEST**

Varicella zoster virus causes chickenpox a highly contagious disease acquired by touching the blisters or respiratory secretions, or through the air. A person is usually infectious 1-2 days before the rash to 4-5 days after the start of the rash, or until the blisters have formed crusts. Symptoms start about 2-3 weeks after exposure and include fever, tiredness, and an itchy rash with small blisters that dry up and form scabs in 2-4 days. More severe but rare problems or complications that could occur are pneumonia (especially in adults), skin infection, blood infection and encephalitis. Approximately 90% of chickenpox cases are in children 1-14 years of age, and 90% of people have had chickenpox by their early 20's. The reactivated form (herpes zoster: shingles) of VZV infection generally occurs in older adults whose immunity has waned, in infants or children exposed to VZV in the perinatal period or in the immunocompromised. VZV infection during pregnancy infrequently leads to maternal pneumonia. Chickenpox can occur during pregnancy in women seropositive for VZV, especially when seropositive at low titer, with low-avidity, largely IgG3 antibodies.

Maternal VZV infection during pregnancy (especially between 13-20 weeks gestation) can be associated with outcomes ranging from skin scarring or limb hypoplasia to multi system involvement and death. Because VZV and herpes simplex virus (HSV) can cross-react, viral culture can be used to detect and differentiate HSV from VZV, but PCR testing may prove the most valuable for diagnosing and differentiating active infection. IgG antibodies can be detected 9 days after the onset of rash in varicella, 10 days in zoster; immunoreactivity peaks at an average 66 and 27 days, respectively. The IgM response to varicella is detected at 6-7 days post-onset and peaks at an average 14 days; IgM response to

zoster is detectable at 8-10 days and peaks at 18-19 days.

#### **PRINCIPLE OF THE TEST**

Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.

#### **MATERIALS PROVIDED**

- Microwell Strips: VZV antigen coated wells (12 x 8 x 1 wells)
- Sample Diluent: 1 bottle (22 mL). Ready to use.
- Calibrator: Yellow Cap. (1.50 mL/vial). Ready to use.
- Positive Control: Red Cap. (1.50 mL/vial). Ready to use.
- Negative Control: Blue Cap. (1.50 mL/vial). Ready to use.
- Enzyme Conjugate: 1 bottle (12 mL). Ready to use.
- TMB Substrate: 1 bottle (12 mL). Ready to use.
- Stop Solution: 1N H<sub>2</sub>SO<sub>4</sub>; 1 bottle (12 mL). Ready to use.
- Wash Concentrate: 1 bottle (50 mL), 20X concentrate.

#### **STORAGE AND STABILITY**

- Store the kit at 2-8°C.
- Keep microwells sealed in a dry bag with desiccants.
- The reagents are stable until expiration of the kit.
- Do not expose test reagents to heat, sun or strong light during storage or usage.

#### **WARNINGS AND PRECAUTIONS**

1. Potential biohazardous materials:

The calibrator and controls contain human source components which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent. These reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health

manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984.

2. Optimal results will be obtained by strict adherence to the test protocol. Precise pipetting as well as following the exact time and temperature requirements is essential.
3. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
4. The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.
5. Control sera and sample diluent contain preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

#### **SPECIMEN COLLECTION AND HANDLING**

1. Collect blood specimens and separate the serum.
2. Specimens may be refrigerated at 2–8°C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing of serum sample.

#### **PREPARATION FOR ASSAY**

1. Bring all specimens and kit reagents to room temperature (20-25°C) and gently mix.
2. Prepare washing buffer by adding the contents of the bottle (50 mL, 20X Wash concentrate) to 950 mL of distilled or deionized water in one-liter container. Store at room temperature.

#### **ASSAY PROCEDURE**

1. Place the desired number of coated strips into the holder.
2. **Negative control, positive control, and calibrator are ready to use.**  
Prepare 1:21 dilution of test samples, by adding 10 µL of the sample to 200 µL of sample diluent. Mix well.
3. Dispense 100 µL of diluted sera, calibrator and controls into the appropriate wells. For the reagent blank, dispense 100 µL sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 20 minutes at room temperature.
4. Remove liquid from all wells. Repeat washing three times with wash buffer.
5. Dispense 100 µL of enzyme conjugate to each well and incubate for 20 minutes at room temperature.
6. Remove enzyme conjugate from all wells. Repeat washing three times with wash buffer.
7. Dispense 100 µL of TMB substrate solution and incubate for 10 minutes at room temperature.
8. Add 100 µL of 1N H<sub>2</sub>SO<sub>4</sub> to stop reaction.

9. Read O.D. within 30 min at 450 nm using microwell reader.

#### **CALCULATION OF RESULTS**

1. Check Calibrator Factor (CF) value on the calibrator bottle. This value might vary from lot to lot. Make sure you check the value on every kit.
2. Calculate the cut-off value: Calibrator OD x Calibrator Factor (CF).
3. Calculate the Ab (Antibody) Index of each determination by dividing the O.D. value of each sample by cut-off value.

#### **Example of typical results:**

Calibrator mean OD = 0.8  
 Calibrator Factor (CF) = 0.5  
 Cut-off Value = 0.8 x 0.5 = 0.400  
 Positive control O.D. = 1.2  
 Ab Index = 1.2 / 0.4 = 3  
 Patient sample O.D. = 1.6  
 Ab Index = 1.6 / 0.4 = 4.0

#### **QUALITY CONTROL**

The test run may be considered valid provided the following criteria are met:

- The O.D. of the Calibrator should be greater than 0.250.
- The Ab index for Negative control should be less than 0.9.
- The Ab Index for Positive control should be greater than 1.2.

#### **INTERPRETATION**

The following is intended as a guide to interpretation of CBI VZV IgG test results ; each laboratory is encouraged to establish its own criteria for test interpretation based on sample populations encountered.

#### **Antibody Index Interpretation**

<0.9 No detectable antibody to VZV IgG by ELISA.  
 0.9-1.1 Borderline positive. Follow-up testing is recommend if clinically indicated.  
 >1.1 Indicative of VZV infection.

#### **LIMITATIONS OF THE TEST**

1. The test results obtained using this kit serve only as an aid to diagnosis and should be interpreted in relation to the patient's history, physical findings and other diagnostic procedures.
2. Lipemic or hemolyzed samples may cause erroneous results.

**PERFORMANCE CHARACTERISTICS**

**1. Sensitivity and Specificity**

212 patient sera were tested by both CBI VZV IgG ELISA and a reference ELISA method. 168 sera were positive and 41 were negative by both methods (98 % agreement).

The results are summarized below:

	CBI VZV IgG ELISA		
	+	-	Total
Reference ELISA	168	1	
+ Kit	169		41
-	43	2	
Total	170	42	
	212		

**2. Precision**

**Intra Assay Study**

Serum	No. of Replicates	Mean	Standard Deviation	Coefficient of Variation%
1	16	1.23	0.071	5.69
2	16	0.61	0.042	6.55
3	16	0.19	0.015	7.89

**Inter Assay Study**

Serum	No. of Replicates	Mean	Standard Deviation	Coefficient of Variation%
1	10	1.78	0.131	7.35
2	10	1.22	0.097	7.95
3	10	0.28	0.025	8.92

**REFERENCES**

- Weinberg A, Hayward AR, Masters HB, Obu IA, Levin MJ. Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster cell-mediated immunity. *J Clin Microbiol* 1996;34:445-6.
- Unadkat P, Newman B, Tedder RS. The detection of varicella zoster antibodies by simultaneous competitive EIA and its comparison with radioimmunoassay, latex agglutination and antiglobulin type EIA. *J Virol Methods* 1995;51:145-52.
- Junker AK, Tilley P. Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox. *J Med Virol* 1994;43:119-24.
- Balfour HH Jr, Edelman CK, Dirksen CL, et al. Laboratory studies of acute varicella and varicella immune status. *Diagn Microbiol Infect Dis* 1988;10:149-58.
- Cohen PR. Tests for detecting herpes simplex virus and varicella-zoster virus infections. *Dermatol Clin* 1994;12:51-68.
- Ghodratnama F; Wray D; Bagg J Detection of serum antibodies against cytomegalovirus, varicella zoster virus and human herpesvirus 6 in patients with recurrent aphthous stomatitis. *J Oral Pathol Med* 1999; 28(1): 12-5.
- Gil A; Gonz´alez A; Dal-R´e R; Ortega P; Dominguez V. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. *J Infect* 1988; 36(1):53-6.